Formation Bio snaps up global rights to next-gen CNS TYK2 inhibitor from Lynk Pharma
LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure
LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
Acetaminophen Injection is indicated for the management of mild to moderate pain in adult and pediatric patients 2 years and older
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Captured microbes are then neutralized on engineered microbicidal surfaces
DUPLEX’s two-compartment, PVC- and DEHP-free design keeps medication and diluent separate until activation
It's an acquisition that aims at forming one of the US's largest oncology trial networks
VitiPure serves as essential solubilizers, emulsifiers, and bioavailability enhancers in drug formulations
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
Subscribe To Our Newsletter & Stay Updated